EGFRvIII Detection Kit
No. of Reactions*
|EGFRvIII Detection Kit||
* Includes all controls
EGFRvIII and Cancer
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer that accounts for approximately 45% of malignant brain tumors. Advancements in molecular profiling and precision medicine have the potential to improve the diagnosis, treatment and prognosis of GBM patients. The discovery of new biomarkers that could become potential targets for treatment is leading to the development of new anti-GBM therapies. EGFRvIII, the most common EGFR mutation in GBM, is found in approximately 60-70% of EGFR-amplified primary GBM tumors and is a potential target for experimental treatments.
EntroGen’s EGFRvIII Detection Kit provides reagents that detect this mutation in total RNA isolated from tumor biopsies in a single step process (RNA to results in one step). Each kit is supplied with primer/probe sets for multiplexed detection of both target and internal control genes.
Testing Procedure and Analysis
The testing procedure involves the following simple steps:
- Isolation of RNA from tumor biopsies, paraffin-embedded sections (FFPE), or fresh frozen tumors.
- Amplification using the provided reagents in the kit.
- Data analysis and interpretation using real-time PCR software.
Equipment & Materials
EntroGen’s EGFRvIII assay requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. The tests include reagents required for PCR amplification/detection, as well as validated reaction controls. Columns and reagents for RNA isolation are not included.
USA: For research use only (RUO). Not for use in diagnostic procedures.
Europe: For research (RUO) and diagnostic (CE-IVD) use.